Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18348906rdf:typepubmed:Citationlld:pubmed
pubmed-article:18348906lifeskim:mentionsumls-concept:C0031330lld:lifeskim
pubmed-article:18348906lifeskim:mentionsumls-concept:C0001128lld:lifeskim
pubmed-article:18348906lifeskim:mentionsumls-concept:C0014898lld:lifeskim
pubmed-article:18348906lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:18348906lifeskim:mentionsumls-concept:C1415306lld:lifeskim
pubmed-article:18348906lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:18348906lifeskim:mentionsumls-concept:C1979963lld:lifeskim
pubmed-article:18348906lifeskim:mentionsumls-concept:C0231491lld:lifeskim
pubmed-article:18348906lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:18348906lifeskim:mentionsumls-concept:C2003903lld:lifeskim
pubmed-article:18348906lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:18348906pubmed:issue8lld:pubmed
pubmed-article:18348906pubmed:dateCreated2008-4-24lld:pubmed
pubmed-article:18348906pubmed:abstractTextIn this paper, we describe the synthesis of (+)-(1R( *),2R( *))-2-[(1S( *))-1-amino-1-carboxy-2-(9H-xanthen-9-yl)-ethyl]-1-fluorocyclopropanecarboxylic acid (+)-16a, a compound, that is, fluorinated at the alpha position of the carboxylic acid in the cyclopropane ring of a group II mGluRs antagonist, 1 (LY341495), using a previously reported stereoselective cyclopropanation reaction. The fluorinated compound (+)-16a exhibited almost the same affinity (IC(50)=3.49 nM) for mGluR2 as 1 but had a superior pharmacokinetic profile. Furthermore, a marked elevation of the plasma levels of (+)-16a was observed following the administration of a prodrug, (+)-17.lld:pubmed
pubmed-article:18348906pubmed:languageenglld:pubmed
pubmed-article:18348906pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18348906pubmed:citationSubsetIMlld:pubmed
pubmed-article:18348906pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18348906pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18348906pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18348906pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18348906pubmed:statusMEDLINElld:pubmed
pubmed-article:18348906pubmed:monthAprlld:pubmed
pubmed-article:18348906pubmed:issn1464-3391lld:pubmed
pubmed-article:18348906pubmed:authorpubmed-author:TaguchiTakeoTlld:pubmed
pubmed-article:18348906pubmed:authorpubmed-author:YasuharaAkito...lld:pubmed
pubmed-article:18348906pubmed:authorpubmed-author:SaitoAkioAlld:pubmed
pubmed-article:18348906pubmed:authorpubmed-author:ChakiShigeyuk...lld:pubmed
pubmed-article:18348906pubmed:authorpubmed-author:YoshikawaRyok...lld:pubmed
pubmed-article:18348906pubmed:authorpubmed-author:NakazatoAtsur...lld:pubmed
pubmed-article:18348906pubmed:authorpubmed-author:KawakitaYasun...lld:pubmed
pubmed-article:18348906pubmed:authorpubmed-author:SakagamiKazun...lld:pubmed
pubmed-article:18348906pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18348906pubmed:day15lld:pubmed
pubmed-article:18348906pubmed:volume16lld:pubmed
pubmed-article:18348906pubmed:ownerNLMlld:pubmed
pubmed-article:18348906pubmed:authorsCompleteYlld:pubmed
pubmed-article:18348906pubmed:pagination4359-66lld:pubmed
pubmed-article:18348906pubmed:meshHeadingpubmed-meshheading:18348906...lld:pubmed
pubmed-article:18348906pubmed:meshHeadingpubmed-meshheading:18348906...lld:pubmed
pubmed-article:18348906pubmed:meshHeadingpubmed-meshheading:18348906...lld:pubmed
pubmed-article:18348906pubmed:meshHeadingpubmed-meshheading:18348906...lld:pubmed
pubmed-article:18348906pubmed:meshHeadingpubmed-meshheading:18348906...lld:pubmed
pubmed-article:18348906pubmed:meshHeadingpubmed-meshheading:18348906...lld:pubmed
pubmed-article:18348906pubmed:meshHeadingpubmed-meshheading:18348906...lld:pubmed
pubmed-article:18348906pubmed:meshHeadingpubmed-meshheading:18348906...lld:pubmed
pubmed-article:18348906pubmed:meshHeadingpubmed-meshheading:18348906...lld:pubmed
pubmed-article:18348906pubmed:meshHeadingpubmed-meshheading:18348906...lld:pubmed
pubmed-article:18348906pubmed:meshHeadingpubmed-meshheading:18348906...lld:pubmed
pubmed-article:18348906pubmed:meshHeadingpubmed-meshheading:18348906...lld:pubmed
pubmed-article:18348906pubmed:year2008lld:pubmed
pubmed-article:18348906pubmed:articleTitleSynthesis, in vitro pharmacology, and pharmacokinetic profiles of 2-[1-amino-1-carboxy-2-(9H-xanthen-9-yl)-ethyl]-1-fluorocyclopropanecarboxylic acid and its 6-heptyl ester, a potent mGluR2 antagonist.lld:pubmed
pubmed-article:18348906pubmed:affiliationMedicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd, Saitama-shi, Saitama 331-9530, Japan. kazunari.sakagami@po.rd.taisho.co.jplld:pubmed
pubmed-article:18348906pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:18348906lld:chembl